Judge Dismisses Tampa General's Suit Against Eli Lilly
A federal judge ruled the hospital had no private remedy to force discounted drug pricing, though the dismissal was without prejudice.
Updated on Nov. 19, 2026 in Industry

A federal judge in Tampa dismissed Tampa General Hospital's lawsuit against drugmaker Eli Lilly & Co. over denied drug discounts. The hospital had said it refused to comply with the manufacturer's new drug discount data requirements.
Why it matters
The ruling leaves unresolved whether hospitals can challenge manufacturer discount conditions in court, a question that affects how safety-net and community hospitals in the Tampa area obtain lower-cost medications. Because the dismissal was without prejudice, the hospital may be able to refile.
The order was issued November 18, 2026, and the dismissal was without prejudice, so the case was closed without a ruling on the merits. Whether the hospital will refile or appeal has not been reported.
The players
Tampa General Hospital
A major nonprofit teaching hospital based in Tampa, Florida, known for its large volume of patient care and its role as a regional referral center.
Eli Lilly & Co.
An Indianapolis-based pharmaceutical company that manufactures widely prescribed medicines, including diabetes and obesity treatments.
William F. Jung
A federal judge serving on the U.S. District Court for the Middle District of Florida, who issued the dismissal order.
The details
Tampa General Hospital sued Eli Lilly in July, saying the drugmaker denied discounts the hospital sought. The hospital said it refused to comply with the manufacturer's new drug discount data requirements. Judge William F. Jung of the U.S. District Court for the Middle District of Florida ruled there is no private remedy to superintend the pricing and provision of discounted drugs.
Timeline
July 2026: Tampa General Hospital sued Eli Lilly over denied drug discounts.
November 18, 2026: Judge Jung dismissed the hospital's challenge without prejudice.
Healthcare Landscape
The case reflects a recurring conflict under the 340B Drug Pricing Program, where drugmakers have imposed data requirements on discounted sales and hospitals have pushed back. Whether courts will provide a remedy for hospitals in such disputes remains an open question.
Patients at hospitals that rely on discounted drug pricing may see the cost of medications affected by how these disputes are resolved. The dismissal without prejudice means the underlying dispute over discounts could return to court, and any change would show up in what hospitals can afford to provide.
The takeaway
Drug discount disputes between manufacturers and hospitals can be dismissed on threshold grounds even when the underlying conflict remains unsettled. Readers following healthcare costs should watch whether the hospital refiles or whether similar suits move forward.
Further reading
For more on the pricing rules shaping hospital operations, explore Healthcare coverage from across the region.
Source note: This article includes information reported by Bloomberglaw.






